LEGN
Legend Biotech CorporationNASDAQHealthcare$19.14+0.47%ClosedMarket Cap: $3.54B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.44
P/S
3.35
EV/EBITDA
-12.18
DCF Value
$-3,174.78
FCF Yield
-6.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
60.3%
Operating Margin
-13.2%
Net Margin
-28.8%
ROE
-29.2%
ROA
-17.1%
ROIC
-9.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $307.6M | 59.7% | $-19.8M | $-31.0M | $-0.17 | — |
| FY 2025 | $1.03B | 60.3% | $-136.9M | $-297.6M | $-1.60 | — |
| Q3 2025 | $272.3M | 57.7% | $-43.5M | $-39.7M | $-0.22 | — |
| Q2 2025 | $255.1M | 61.6% | $-21.9M | $-125.4M | $-0.68 | — |
| Q1 2025 | $195.1M | 63.4% | $-50.6M | $-100.9M | $-0.55 | — |
| Q4 2024 | $186.5M | 60.4% | $-74.4M | $26.3M | $0.14 | — |
| FY 2024 | $627.2M | 62.6% | $-303.2M | $-177.0M | $-0.97 | — |
| Q3 2024 | $160.2M | 65.4% | $-70.0M | $-125.3M | $-0.68 | — |
| Q2 2024 | $186.5M | 73.0% | $-42.0M | $-18.2M | $-0.10 | — |
| Q1 2024 | $94.0M | 41.8% | $-117.9M | $-59.8M | $-0.33 | — |
| Q4 2023 | $79.5M | 59.2% | $-119.8M | $-144.8M | $-0.80 | — |
| FY 2023 | $285.1M | 49.4% | $-439.5M | $-518.3M | $-2.94 | — |